TheryCell GmbH

TheryCell brings together experts in T-cell analysis, bioinformatics, and molecular biology. Our mission is clear: to pioneer a novel therapy against various cancers based on tumor-reactive T-cells. Our patented technology, tested in dozens of tumor samples, is actively proving the tumor-killing potential of our dedicated T-cell selections in collaborations with clinics and research institutes. TheryCell collaborates with clinics and research institutes, combining a unique bioinformatics platform with high-throughput NGS of T-cell receptor compounds and single-cell sequencing (10Xgenomics) to manufacture dedicated, tumor-specific T-cells. Focusing on natural tumor-specific T-cell receptors (TCRs), we identify T-cells that escaped negative selection and evolved into dominant tumor-specific T-cell clones after encountering tumor antigens. Our proprietary technologies in immune-sequencing and special tissue handling decipher complex T-cell repertoires in the tumor (TILs). Sequencing alpha/beta TCRs provides the foundation for a tumor-specific personalized TCR-gene therapy. TheryCell envisions a future where personalized TCR-gene therapy offers high safety and efficacy, fully compatible with the patient's individual HLA subtypes. Join us at TheryCell GmbH, where innovation meets commitment, shaping the future of personalized cancer immunotherapy. #TheryCell #Immunotherapy #CancerResearch #InnovationInHealthcare